Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Breast 1

Conditions

Neoplasm Metastasis 5Prostatic Neoplasms 3Breast Neoplasms 3Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Non-Small Cell Lunch Cancer 1Non Castrate Metastatic Prostate Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Basal Cell 1Basal Cell Nevus Syndrome 1

Interventions

Temozolomide 28Radiosurgery 19Radiotherapy 17Bevacizumab 12Magnetic Resonance Spectroscopy 9Radiation 6Erlotinib Hydrochloride 6Carboplatin 6Topotecan 5Nivolumab 5Mental Status and Dementia Tests 5Irinotecan 5Capecitabine 5pembrolizumab 4dabrafenib 4Trastuzumab 4Sunitinib 4Pemetrexed 4Ipilimumab 4Filgrastim 4Cyclophosphamide 4Aminolevulinic Acid 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4cabozantinib 3Vorinostat 3TPI-287 3Specimen Handling 3Radiotherapy, Intensity-Modulated 3Methylphenidate 3Lomustine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Brain Neoplasms × NVP-BKM120 × Clear all
NCT01870726 2018-05-30

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Novartis

Phase 1/2 Terminated
43 enrolled 22 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01132664 2016-08-17

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Novartis

Phase 1/2 Terminated
72 enrolled 15 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡